Tanner offers pharmaceutical companies a lower-cost alternative to bridge treatment for trial patients until a medicine is commercially available.
HOW IT WORKS
When a clinical trial has finished, pharmaceutical companies are typically obligated to continue supplying patients with the investigational medicine until it is commercially available. Additionally, if a medicine has failed its clinical trial or the pharmaceutical company has decided to discontinue development, there may still be obligations to supply the study medicine for patients who benefited. As a result, pharmaceutical companies continue to incur costs and utilize resources until trial sites are closed. Tanner offers pharmaceutical companies a lower-cost alternative to bridge treatment for trial patients until a medicine is commercially available.
OUR ACCESS SOLUTIONS
From Early-Access to Compassionate Use, we take a comprehensive approach to access solutions.
Expanded Access Programs
US FDA regulated pathways that allow provision of investigational new drugs (INDs) to patients with serious diseases or conditions who have exhausted approved therapy and cannot participate in a clinical trial.
The use of a new, unapproved drug to treat a seriously ill patient when no other treatments are available.
A program to maintain supply of the medicine to patients until it becomes commercially available.
Early Access Programs
Allow pre-approval access to medicines for certain patients
Utilizing our existing global network and supply chain, TannerGMS has partnered with various PPE and diagnostic manufacturers and has created direct distribution pathways to deliver necessary COVID-related medical supplies around the world.
Programs for pharmaceutical companies that are seeking to donate their medicines in low- and middle-income countries where patients do not have the insurance or financial means to pay for them.
A service that sets up the infrastructure to respond to supply chain disruptions that can cause drug shortages and mitigate the impact on patient access to their medicines.
Providing ways to access a market post-withdrawal where demand from physicians and patients remain, and we can help.
We have the ability to access all products for request internationally – finding access to products in unmet demand of markets of need. We do this through NPP (processed through import).
Clinical Supply Gatekeeper
We can help you effectively manage inbound requests for comparators and reference listed drugs.